Last $138.08 USD
Change Today -2.23 / -1.59%
Volume 1.6M
BDX On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:04 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

becton dickinson and co (BDX) Snapshot

Open
$139.05
Previous Close
$140.31
Day High
$139.99
Day Low
$138.01
52 Week High
01/8/15 - $146.74
52 Week Low
02/3/14 - $105.21
Market Cap
26.7B
Average Volume 10 Days
1.1M
EPS TTM
$6.08
Shares Outstanding
193.4M
EX-Date
03/6/15
P/E TM
22.7x
Dividend
$2.40
Dividend Yield
1.62%
Current Stock Chart for BECTON DICKINSON AND CO (BDX)

becton dickinson and co (BDX) Related Businessweek News

View More BusinessWeek News

becton dickinson and co (BDX) Details

Becton, Dickinson and Company, a medical technology company, develops, manufactures, and sells medical devices, instrument systems, and reagents worldwide. The company’s BD Medical segment produces medical devices, such as needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; syringes and pen needles for use in the treatment of diabetes; prefillable drug delivery systems; anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; and generic prefilled injectables. Its BD Diagnostics segment provides products for the collection and transportation of diagnostics specimens; and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections, and cancers. This segment’s products include integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood and tuberculosis culturing systems; molecular testing systems; microorganism identification and drug susceptibility systems; liquid-based cytology systems; rapid diagnostic assays; microbiology laboratory automation; and plated media. The company’s BD Medical segment offers research and clinical tools, such as fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; diagnostic assays; and cell culture media supplements for biopharmaceutical manufacturing. It also develops technologies that address biological analysis protocols, including library preparation of next generation sequencing and genotyping applications. The company markets its products through independent distribution channels and sales representatives to healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.

30,619 Employees
Last Reported Date: 11/26/14
Founded in 1897

becton dickinson and co (BDX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $985.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $690.2K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $721.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $900.8K
Executive Vice President
Total Annual Compensation: $605.7K
Compensation as of Fiscal Year 2014.

becton dickinson and co (BDX) Key Developments

Becton, Dickinson and Company Reports Sales Results for the Year 2014; Provides Earnings Guidance for the Year 2015

Becton, Dickinson and Company reported sales results for the year 2014. For the period, the company's revenue growth was robust at 5.2%, which includes 20 basis points of growth from acquisitions. For fiscal year 2015, the company anticipates organic currency-neutral revenue growth of 4.5% to 5%. This year, the company expects it to grow earnings by about 9% to 10% on an underlying basis. The unfavorable impact of the suspension of share repurchase program is worth about 100 basis points, bringing currency-neutral earnings growth to 8% to 9%.

Becton, Dickinson Mulls Acquisitions

Becton, Dickinson and Company (NYSE:BDX) intends to make acquisitions. Vince Forlenza, Chairman and Chief Executive Officer of the company said: “While our near-term priority is to pay down debt, we will continue to look for strategic plug-in acquisition opportunities that align with our capabilities and create shareholder value. Our goal is to complement organic growth through bolt-on acquisitions and help accelerate moves into near adjacencies that create more powerful impactful solutions for customers.”

BD Medical's Bd™ Intelliport® Medication Management System Receives Clearance from the Food and Drug Administration

BD Medical, a segment of BD (Becton, Dickinson and Company) announced that the U.S. Food and Drug Administration (FDA) has cleared the BD™ Intelliport® Medication Management System, the first-of-its-kind medication management solution for manual IV bolus injections. The Intelliport System is the solution to provide real-time drug identification, dose measurement and allergy detection at the point of injection, while wirelessly sending captured information directly into the patient's electronic medical record (EMR) following medication administration. With this new FDA clearance, BD can offer healthcare workers advanced, smart-injection-site functionality and access to medication administration information at the point-of-care. By combining the Intelliport System's unique IV access site sensor with a rechargeable, wireless base and touch-screen tablet technology, integrated with hospital information systems, essential medical information can be recorded instantaneously, following patients throughout their perioperative stay. The Intelliport System is expected to be commercially available in spring 2015. With this FDA clearance, and for the first time in the hospital setting, real-time drug identification, dose measurement and automatic documentation will be delivered in one solution which may help manage the leading causes of medication errors in the operating room, including inadvertent substitution (syringe swap) and dosing errors.1, 2 The Intelliport System's automatic documentation feature may also reduce manual documentation efforts and improve accuracy by wirelessly sending medication administration information on drug, dose and time directly into a patient's EMR. The first live demonstration of the Intelliport System since receiving FDA clearance will be held during the Society for Technology in Anesthesia (STA) 2015 Annual Meeting taking place January 7-10 at the Royal Palms Resort in Phoenix, Arizona.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BDX:US $138.08 USD -2.23

BDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,830 JPY +6.50
Boston Scientific Corp $14.81 USD -0.04
Ecolab Inc $103.77 USD -0.61
Illumina Inc $195.19 USD -4.81
Zimmer Holdings Inc $112.10 USD -0.42
View Industry Companies
 

Industry Analysis

BDX

Industry Average

Valuation BDX Industry Range
Price/Earnings 23.0x
Price/Sales 3.1x
Price/Book 5.2x
Price/Cash Flow 23.8x
TEV/Sales 2.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BECTON DICKINSON AND CO, please visit www.bd.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.